Free Trial

Panbela Therapeutics Q2 2023 Earnings Report

Panbela Therapeutics logo
$0.34 +0.01 (+3.98%)
As of 03/28/2025 03:36 PM Eastern

Panbela Therapeutics EPS Results

Actual EPS
-$159.00
Consensus EPS
-$94.20
Beat/Miss
Missed by -$64.80
One Year Ago EPS
-$36,276.20

Panbela Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Panbela Therapeutics Announcement Details

Quarter
Q2 2023
Time
After Market Closes
Remove Ads

Panbela Therapeutics Earnings Headlines

Panbela Therapeutics Announces Q3 2024 Financial Results
This trading frustration almost made me quit
This happened to me time and time again, and I wanted no more of it. That’s exactly why I set out to refine my strategy… And with the help of my good friend Nate, we have done exactly that… Now, I cannot promise future returns or against losses, but the real trades so far have been nothing but astounding. Turning my once 69% win rate, into 83.3% on real trades in the last two months. And instead of just telling you, I want to SHOW you.
See More Panbela Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Panbela Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Panbela Therapeutics and other key companies, straight to your email.

About Panbela Therapeutics

Panbela Therapeutics (NASDAQ:PBLA), a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

View Panbela Therapeutics Profile

More Earnings Resources from MarketBeat